GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HPGC Renmintongtai Pharmaceutical Corp (SHSE:600829) » Definitions » Beneish M-Score

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Beneish M-Score : -2.13 (As of Dec. 12, 2024)


View and export this data going back to 1994. Start your Free Trial

What is HPGC Renmintongtai Pharmaceutical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.13 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for HPGC Renmintongtai Pharmaceutical's Beneish M-Score or its related term are showing as below:

SHSE:600829' s Beneish M-Score Range Over the Past 10 Years
Min: -3.23   Med: -2.12   Max: -0.8
Current: -2.13

During the past 13 years, the highest Beneish M-Score of HPGC Renmintongtai Pharmaceutical was -0.80. The lowest was -3.23. And the median was -2.12.


HPGC Renmintongtai Pharmaceutical Beneish M-Score Historical Data

The historical data trend for HPGC Renmintongtai Pharmaceutical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HPGC Renmintongtai Pharmaceutical Beneish M-Score Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.63 -2.25 -1.74 -2.45 -2.42

HPGC Renmintongtai Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.43 -2.42 -2.21 -2.11 -2.13

Competitive Comparison of HPGC Renmintongtai Pharmaceutical's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, HPGC Renmintongtai Pharmaceutical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HPGC Renmintongtai Pharmaceutical's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HPGC Renmintongtai Pharmaceutical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where HPGC Renmintongtai Pharmaceutical's Beneish M-Score falls into.



HPGC Renmintongtai Pharmaceutical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of HPGC Renmintongtai Pharmaceutical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9745+0.528 * 1.0577+0.404 * 1.1321+0.892 * 1.0032+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6804+4.679 * 0.046008-0.327 * 0.938
=-2.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥4,567 Mil.
Revenue was 2692.556 + 2387.493 + 2598.035 + 2565.011 = ¥10,243 Mil.
Gross Profit was 228.575 + 210.588 + 241.946 + 259.169 = ¥940 Mil.
Total Current Assets was ¥6,540 Mil.
Total Assets was ¥7,031 Mil.
Property, Plant and Equipment(Net PPE) was ¥336 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥104 Mil.
Total Current Liabilities was ¥4,012 Mil.
Long-Term Debt & Capital Lease Obligation was ¥20 Mil.
Net Income was 70.812 + 56.858 + 78.334 + 51.622 = ¥258 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -38.107 + 131.107 + -336.297 + 177.44 = ¥-66 Mil.
Total Receivables was ¥4,671 Mil.
Revenue was 2549.753 + 2621.819 + 2653.397 + 2384.982 = ¥10,210 Mil.
Gross Profit was 242.798 + 251.245 + 243.21 + 254.086 = ¥991 Mil.
Total Current Assets was ¥6,781 Mil.
Total Assets was ¥7,274 Mil.
Property, Plant and Equipment(Net PPE) was ¥352 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥152 Mil.
Total Current Liabilities was ¥4,420 Mil.
Long-Term Debt & Capital Lease Obligation was ¥27 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4566.865 / 10243.095) / (4671.122 / 10209.951)
=0.445848 / 0.457507
=0.9745

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(991.339 / 10209.951) / (940.278 / 10243.095)
=0.097095 / 0.091796
=1.0577

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6540.141 + 335.554) / 7030.987) / (1 - (6780.706 + 351.695) / 7274.323)
=0.022087 / 0.01951
=1.1321

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10243.095 / 10209.951
=1.0032

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 351.695)) / (0 / (0 + 335.554))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(103.615 / 10243.095) / (151.794 / 10209.951)
=0.010116 / 0.014867
=0.6804

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((20.452 + 4011.997) / 7030.987) / ((27.447 + 4420.207) / 7274.323)
=0.573525 / 0.611418
=0.938

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(257.626 - 0 - -65.857) / 7030.987
=0.046008

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

HPGC Renmintongtai Pharmaceutical has a M-score of -2.13 suggests that the company is unlikely to be a manipulator.


HPGC Renmintongtai Pharmaceutical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of HPGC Renmintongtai Pharmaceutical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


HPGC Renmintongtai Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.
Executives
Yue Xian Zhi senior management
Zhang Li Jun Director

HPGC Renmintongtai Pharmaceutical Headlines

No Headlines